News | News By Subject | News by Disease News By Date | Search News

Rheumatoid arthritis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Success of Pfizer (PFE)’s Humira Biosimilar for Rheumatoid Arthritis in Phase III Bodes Well for Its Strong Biosimilar Pipeline     1/23/2017
Going Up Against AbbVie (ABBV)'s Humira, Johnson & Johnson (JNJ) Presents Less-Than-Stellar Phase III Data     11/14/2016
OUCH! FDA Spurns Regeneron (REGN), Sanofi (SNY)'s RA Drug Over Plant Deficiencies     11/1/2016
Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme (SNY)'s Next Blockbuster     10/31/2016
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF)     10/20/2016
3 Healthcare Giants Are All Trying to Take a Bite Out of AbbVie (ABBV)'s Humira Domination     10/14/2016
FDA Clears Amgen (AMGN) Copy of AbbVie (ABBV)'s Blockbuster Humira     9/26/2016
Ablynx (ABLYF) Reports Compelling Topline Phase Ilb Study Results With Its Anti-Il-6r Nanobody, Vobarilizumab, In RA Patients, Confirming Its Best-In-Class Potential     8/9/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research     7/18/2016
Amgen (AMGN) Inches Closer to Selling Cheaper Version of AbbVie (ABBV)'s Blockbuster Humira     7/13/2016
FDA Staff Says Novartis AG (NVS) Copy of Amgen (AMGN)'s Blockbuster Enbrel is 'Highly Similar'     7/11/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study     7/8/2016
FDA Staff Says Amgen (AMGN) Biosimilar is 'Highly Similar' to AbbVie (ABBV)'s Blockbuster Humira     7/8/2016
Investors Look to the Future of AbbVie (ABBV) Post-Patent Protection for Humira     7/8/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study     6/8/2016

News from Around the Web
Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, University of Amsterdam Study Shows     7/5/2016
Green Tea Compound May Block Rheumatoid Arthritis, Washington State University Study     2/17/2016
Occupational Textile Dust Exposure Linked To Rheumatoid Arthritis, Study Published In BMJ     1/15/2016
Your Diet May Determine Rheumatoid Arthritis Risk, Brigham and Women's Hospital Study     11/9/2015
Could Oral Contraceptives Help Ease Rheumatoid Arthritis? Rheumatism Research Centre Study     8/31/2015
Drug Flops From 2004 Haunt AstraZeneca PLC (AZN) Investors     5/23/2014
Chinese Herb As Effective As Arthritis Pain Drug, Annals of the Rheumatic Diseases Reveals     4/16/2014
Extra Pounds Linked to Rheumatoid Arthritis Risk in Women, Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health Reveals     11/12/2012
Rheumatoid Arthritis Drugs May Help Curb Diabetes Development, Journal of the American Medical AssociationStudy Finds     6/22/2011
EULAR: Rituximab Plus Other Biologics Safe in RA     6/1/2011
Study Identifies Novel Role for a Protein That Could Lead to New Treatments for Rheumatoid Arthritis, Hospital for Special Surgery Study     5/23/2011
Lupus, Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm, University of Arkansas for Medical Sciences Study     5/9/2011
Recent Rituximab Trial with TNF Inhibitors Reports No New Safety Risks in Patients with Rheumatoid Arthritis, Desert Medical Advances Study     3/8/2011
Smoking May Interfere With Rheumatoid Arthritis Treatment, Karolinska University Hospital Study     1/6/2011
New Rheumatoid Arthritis Response Score Validated, Karolinska Institute Study     1/3/2011

Press Releases
Pfizer (PFE) Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     3/16/2017
Celltex Therapeutics Corporation Autologous Stem Cell Case Study Published In Stem Cells And Development Demonstrates Favorable Response In Pediatric Patients     3/13/2017
Sanofi Genzyme (SNY) Release: Kevzara (Sarilumab) Now Available In Canada For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     2/28/2017
CEL-SCI (CVM) Scientist Presents New Findings For Rheumatoid Arthritis Treatment Vaccine At Conference     2/21/2017
Eli Lilly (LLY) Release: Additional Results From Pivotal RA-BEAM Study Published In The New England Journal of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo     2/16/2017
Eli Lilly (LLY) Release: European Commission (EC) Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis     2/14/2017
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis     2/8/2017
Regeneron (REGN) And Sanofi (SNY) Announce First Approval Of Kevzara (Sarilumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis In Adult Patients By Health Canada     2/1/2017
Pfizer (PFE) Receives Positive CHMP Opinion In Europe For XELJANZ (Tofacitinib Citrate) For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis     1/27/2017
Boehringer Ingelheim Release: Company's Biosimilar Candidate To Humira® Accepted For EMA And FDA Regulatory Review     1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA     1/18/2017
Eli Lilly (LLY)-Incyte (INCY) Release: The FDA Wants More Time to Review Baricitinib     1/16/2017
Pfizer (PFE) Announces Positive Top-Line Results From The Comparative REFLECTIONS B538-02 Study For PF-06410293, A Potential Biosimilar To Humira1 (Adalimumab)     1/5/2017
Bird Rock Bio Receives Approval From ANVISA And CONEP To Initiate The First Phase 2 Study In Brazil Of Gerilimzumab For Rheumatoid Arthritis     1/3/2017
Crescendo Bioscience Release: United Rheumatology Issues Clinical Practice Guidelines And Recommends The Vectra DA Test For Adults With Rheumatoid Arthritis     12/27/2016

//-->